Chronic Pelvic Pain
Conditions
Brief summary
This phase II trial attempts to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease.
Detailed description
Chronic pelvic pain is the major sequela of pelvic inflammatory disease and it's a common, burdensome, and costly condition that disproportionately affects women. This multicenter, randomized, double-blind, dose-parallel, placebo-controlled phase II clinical trial is designed to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease. In this trial, 180 subjects were enrolled and randomized to either high-dose Jincaopian Tablets group, low-dose Jincaopian Tablets group, or the placebo group in a 1:1:1 ratio. The treatment period is 12 weeks and the follow-up period is 4 weeks. The outcome measures of chronic pelvic pain relief in this trial are pain visual analog scale (VAS), modified McCormick scale and SF-12 Score.
Interventions
DRUGJincaopian Tablets high dose
Jincaopian Tablets 0.2g tid p.o.
DRUGJincaopian Tablets low dose
Jincaopian Tablets 0.1g tid p.o.
OTHERPlacebo
Placebo tid p.o.
Sponsors
Beijing Konruns Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease; * The average VAS score of pain in the week before enrollment is ≥4; * The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points); * Women aged 18 to 55 (including 18 and 55) with a history of sexual life; * Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.
Exclusion criteria
* Pelvic inflammatory disease (acute attack); * Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 3 months after the trial; * Critically ill or with surgical indications; * Previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases; * Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, etc.; * Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms; * Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages; * Received related treatment or took drugs with similar functions and indications within 14 days before the introduction; * Have a history of allergy to the components of the test drug; * Participated in other clinical trials within the past 3 months; * The investigator believes that it is not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain Visual Analog Scale (VAS) | Baseline to 16 weeks | To measure patient's pain intensity (most commonly) along a 100 mm horizontal line daily. |
| Modified McCormick Scale | Baseline and at Weeks 4, 8, 12, 16 | To evaluate the total score of the physical sign scale and the scores of each part including abdominal tenderness, rebound tenderness, and gynecological examination compared with the baseline in each group at weeks 4, 8, 12, 16. |
| SF-12 Score | Baseline and at Weeks 12 | To evaluate the health status of the patients compared with the baseline in each group at weeks 12. |
Countries
China
Outcome results
None listed